社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
文耕者
IP属地：北京
+关注
帖子 · 103
帖子 · 103
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
文耕者
文耕者
·
2022-11-15
$沃森生物(300142)$
疫苗行业春天来了，大机遇重回沃森
看
2,867
回复
评论
点赞
1
编组 21备份 2
分享
举报
文耕者
文耕者
·
2022-11-15
春天来了
沃森生物：mRNA新冠疫苗获临床试验伦理快速审查批件
沃森生物mRNA新冠疫苗研发取得新进展。 11月15日晚间，云南沃森生物技术股份有限公司发布公告称，公司于近日收到广州医科大学附属第一医院医学伦理委员会关于“评价新型冠状病毒变异株mRNA疫苗序贯加强免疫接种的免疫原性和安全性的随机、盲法、阳性对照Ⅲa期临床试验”的《临床试验快速审查批件》，审查意见为：批准按照已通过审查的临床试验方案和文件开展本项试验研究。
沃森生物：mRNA新冠疫苗获临床试验伦理快速审查批件
看
1,767
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-12-29
$BioNTech SE(BNTX)$
双底将成，准备抄底，新一轮机会，价值区间
看
2,248
回复
评论
点赞
2
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-10-06
副作用太大了，恐难以获批
欧洲药品管理局或将加速评估默克的新冠口服药
格隆汇10月5日丨据彭博，欧洲药品管理局(EMA)将考虑启动针对默克新冠口服药的加速评估进程。该公司上周宣布将尽快寻求美国食品药品管理局(FDA)的紧急使用授权。
欧洲药品管理局或将加速评估默克的新冠口服药
看
1,408
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-10-05
今天目标是要收复失地
@文耕者：
$BioNTech SE(BNTX)$只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。
$BioNTech SE(BNTX)$只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。
看
1,812
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-10-04
$BioNTech SE(BNTX)$
只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。
看
4,755
回复
3
点赞
3
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-10-01
$Moderna, Inc.(MRNA)$
老套路了，别上当。特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。
看
5,194
回复
2
点赞
12
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-10-01
$BioNTech SE(BNTX)$
老套路了，特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。
看
3,832
回复
1
点赞
8
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-09-21
$BioNTech SE(BNTX)$
准备抄个底[微笑]
看
1,973
回复
评论
点赞
2
编组 21备份 2
分享
举报
文耕者
文耕者
·
2021-08-16
$BioNTech SE(BNTX)$
V起来？多空双杀！
看
2,781
回复
评论
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3517894607158463","uuid":"3517894607158463","gmtCreate":1554801518597,"gmtModify":1584698185383,"name":"文耕者","pinyin":"wgzwengengzhe","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":8,"tweetSize":103,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":667942088,"gmtCreate":1668524087944,"gmtModify":1668524088830,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/300142\">$沃森生物(300142)$ </a>疫苗行业春天来了，大机遇重回沃森","listText":"<a href=\"https://laohu8.com/S/300142\">$沃森生物(300142)$ </a>疫苗行业春天来了，大机遇重回沃森","text":"$沃森生物(300142)$ 疫苗行业春天来了，大机遇重回沃森","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667942088","isVote":1,"tweetType":1,"viewCount":2867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":667946554,"gmtCreate":1668524045878,"gmtModify":1668524047556,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"春天来了","listText":"春天来了","text":"春天来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667946554","repostId":"2283293037","repostType":2,"repost":{"id":"2283293037","kind":"news","pubTimestamp":1668512940,"share":"https://www.laohu8.com/m/news/2283293037?lang=&edition=full","pubTime":"2022-11-15 19:49","market":"sh","language":"zh","title":"沃森生物：mRNA新冠疫苗获临床试验伦理快速审查批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2283293037","media":"澎湃新闻","summary":"沃森生物mRNA新冠疫苗研发取得新进展。 11月15日晚间，云南沃森生物技术股份有限公司发布公告称，公司于近日收到广州医科大学附属第一医院医学伦理委员会关于“评价新型冠状病毒变异株mRNA疫苗序贯加强免疫接种的免疫原性和安全性的随机、盲法、阳性对照Ⅲa期临床试验”的《临床试验快速审查批件》，审查意见为：批准按照已通过审查的临床试验方案和文件开展本项试验研究。","content":"<div>\n<p>沃森生物mRNA新冠疫苗研发取得新进展。\n 11月15日晚间，云南沃森生物技术股份有限公司（300142，下称沃森生物）发布公告称，公司于近日收到广州医科大学附属第一医院医学伦理委员会关于“评价新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）序贯加强免疫接种的免疫原性和安全性的随机、盲法、阳性对照Ⅲa期临床试验”的《临床试验快速审查批件》，审查意见为：批准按照已通过审查的临床试验方案和文件开展本项...</p>\n\n<a href=\"https://finance.sina.com.cn/jjxw/2022-11-15/doc-imqqsmrp6296242.shtml\">Web Link</a>\n\n</div>\n","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>沃森生物：mRNA新冠疫苗获临床试验伦理快速审查批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n沃森生物：mRNA新冠疫苗获临床试验伦理快速审查批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-15 19:49 北京时间 <a href=https://finance.sina.com.cn/jjxw/2022-11-15/doc-imqqsmrp6296242.shtml><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>沃森生物mRNA新冠疫苗研发取得新进展。\n 11月15日晚间，云南沃森生物技术股份有限公司（300142，下称沃森生物）发布公告称，公司于近日收到广州医科大学附属第一医院医学伦理委员会关于“评价新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）序贯加强免疫接种的免疫原性和安全性的随机、盲法、阳性对照Ⅲa期临床试验”的《临床试验快速审查批件》，审查意见为：批准按照已通过审查的临床试验方案和文件开展本项...</p>\n\n<a href=\"https://finance.sina.com.cn/jjxw/2022-11-15/doc-imqqsmrp6296242.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"159646":"疫苗","300142":"沃森生物","BK0239":"医药制造","BK0077":"质押式回购","03347":"泰格医药","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1583":"高瓴概念","BK0070":"员工持股","BK0046":"生物疫苗"},"source_url":"https://finance.sina.com.cn/jjxw/2022-11-15/doc-imqqsmrp6296242.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2283293037","content_text":"沃森生物mRNA新冠疫苗研发取得新进展。\n 11月15日晚间，云南沃森生物技术股份有限公司（300142，下称沃森生物）发布公告称，公司于近日收到广州医科大学附属第一医院医学伦理委员会关于“评价新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）序贯加强免疫接种的免疫原性和安全性的随机、盲法、阳性对照Ⅲa期临床试验”的《临床试验快速审查批件》，审查意见为：批准按照已通过审查的临床试验方案和文件开展本项试验研究。\n 据此前公告，新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）是一款针对新冠病毒变异株设计开发，编码全长S蛋白嵌合体的创新型广谱新冠mRNA疫苗，具有自主知识产权。临床前研究表明，该疫苗具有良好的安全性和保护效果，对包括Omicron株在内的主要新型冠状病毒VOCs均具有一定的交叉中和能力。\n 该疫苗由沃森生物与复旦大学、上海蓝鹊生物医药有限公司共同研发，已于2022年8月获批进入临床，公司已启动该疫苗临床研究相关工作。本次批准的临床试验为本疫苗的国内多中心IIIa 期临床试验，广州医科大学附属第一医院为其中的一个临床试验分中心。\n 沃森生物表示，由于新型冠状病毒的不断变异，该疫苗临床试验的进度和结果存在一定的不确定性。本次获得《临床试验快速审查批件》对公司近期业绩不会产生重大影响。\n 官网资料显示，沃森生物创立于2001年，总部位于昆明，是国内专业从事疫苗、血液制品等生物药品研发、生产、销售的现代生物制药企业，已于2010年在深圳证券交易所创业板上市。\n 据2022年三季报披露，沃森生物今年前三季度整体营收37.06亿元，归母净利润5.31亿元，同比分别增长74.06%和45.84%。其中，沃森生物第三季度单季营收13.58亿元，同比增长74.24%；归母净利润1.1亿元，同比增长144.35%。\n 截至11月15日收盘，沃森生物报42.57元/股，总市值683.36亿元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：李墨轩","news_type":1},"isVote":1,"tweetType":1,"viewCount":1767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696724991,"gmtCreate":1640776396122,"gmtModify":1640776396122,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>双底将成，准备抄底，新一轮机会，价值区间","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>双底将成，准备抄底，新一轮机会，价值区间","text":"$BioNTech SE(BNTX)$双底将成，准备抄底，新一轮机会，价值区间","images":[{"img":"https://static.tigerbbs.com/082d88304bfd1c22addd88faae06d0b2","width":"3968","height":"2976"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696724991","isVote":1,"tweetType":1,"viewCount":2248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":829804505,"gmtCreate":1633484480626,"gmtModify":1633484480626,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"副作用太大了，恐难以获批","listText":"副作用太大了，恐难以获批","text":"副作用太大了，恐难以获批","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829804505","repostId":"2173040919","repostType":2,"repost":{"id":"2173040919","kind":"news","pubTimestamp":1633445280,"share":"https://www.laohu8.com/m/news/2173040919?lang=&edition=full","pubTime":"2021-10-05 22:48","market":"hk","language":"zh","title":"欧洲药品管理局或将加速评估默克的新冠口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2173040919","media":"格隆汇","summary":"格隆汇10月5日丨据彭博，欧洲药品管理局(EMA)将考虑启动针对默克新冠口服药的加速评估进程。该公司上周宣布将尽快寻求美国食品药品管理局(FDA)的紧急使用授权。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=106.MRK&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1\" width=\"578\"/></p><p> 格隆汇10月5日丨据彭博，欧洲药品管理局(EMA)将考虑启动针对<span>默克</span><span></span>新冠口服药的加速评估进程。该公司上周宣布将尽快寻求美国食品药品管理局(FDA)的紧急使用授权。</p><p>（文章来源：格隆汇）</p>\n</div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>欧洲药品管理局或将加速评估默克的新冠口服药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n欧洲药品管理局或将加速评估默克的新冠口服药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 22:48 北京时间 <a href=http://finance.eastmoney.com/a/202110052129200067.html><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇10月5日丨据彭博，欧洲药品管理局(EMA)将考虑启动针对默克新冠口服药的加速评估进程。该公司上周宣布将尽快寻求美国食品药品管理局(FDA)的紧急使用授权。（文章来源：格隆汇）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202110052129200067.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","relate_stocks":{},"source_url":"http://finance.eastmoney.com/a/202110052129200067.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2173040919","content_text":"格隆汇10月5日丨据彭博，欧洲药品管理局(EMA)将考虑启动针对默克新冠口服药的加速评估进程。该公司上周宣布将尽快寻求美国食品药品管理局(FDA)的紧急使用授权。（文章来源：格隆汇）","news_type":1},"isVote":1,"tweetType":1,"viewCount":1408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820786722,"gmtCreate":1633434038276,"gmtModify":1633434842332,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"今天目标是要收复失地","listText":"今天目标是要收复失地","text":"今天目标是要收复失地","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820786722","repostId":"820955527","repostType":1,"repost":{"id":820955527,"gmtCreate":1633345356452,"gmtModify":1633345356452,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。","text":"$BioNTech SE(BNTX)$只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820955527","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820955527,"gmtCreate":1633345356452,"gmtModify":1633345356452,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。","text":"$BioNTech SE(BNTX)$只要今天不破上周五低点，基本确认短期底部，就是入场捡筹码的时间了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/820955527","isVote":1,"tweetType":1,"viewCount":4755,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864671200,"gmtCreate":1633100874516,"gmtModify":1633100874516,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>老套路了，别上当。特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>老套路了，别上当。特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。","text":"$Moderna, Inc.(MRNA)$老套路了，别上当。特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/864671200","isVote":1,"tweetType":1,"viewCount":5194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864673527,"gmtCreate":1633100818605,"gmtModify":1633100818605,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>老套路了，特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>老套路了，特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。","text":"$BioNTech SE(BNTX)$老套路了，特效药打压疫苗股，然后疫苗加强针出来，又拉升疫苗股。实际上，特效药和疫苗不矛盾，一个治疗，另一个阻断，并不能相互替代。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864673527","isVote":1,"tweetType":1,"viewCount":3832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869953775,"gmtCreate":1632237297097,"gmtModify":1632237297097,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>准备抄个底[微笑] ","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>准备抄个底[微笑] ","text":"$BioNTech SE(BNTX)$准备抄个底[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/869953775","isVote":1,"tweetType":1,"viewCount":1973,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":839196849,"gmtCreate":1629125303381,"gmtModify":1629125303381,"author":{"id":"3517894607158463","authorId":"3517894607158463","name":"文耕者","avatar":"https://static.tigerbbs.com/6fd9ffa1fcca07d6297b66c9da40817e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3517894607158463","authorIdStr":"3517894607158463"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>V起来？多空双杀！","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>V起来？多空双杀！","text":"$BioNTech SE(BNTX)$V起来？多空双杀！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839196849","isVote":1,"tweetType":1,"viewCount":2781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}